TheStreet Quant Ratings rates CytRx Corporation (NASDAQ:CYTR) as a sell. The company’s weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, poor profit margins, weak operating cash flow and feeble growth in its earnings per share. CytRx Corporation (NASDAQ:CYTR) stock opened at $6.26 in last trading session, and closed at $5.92, trading in the range of $5.83 – $6.37. The stock showed a negative weekly performance of -10.84%.
Research firm Ladenburg Thalmann upgraded Genetic Technologies Limited (ADR) (NASDAQ:GENE) stock to buy from neutral. Genetic Technologies Limited (ADR) (NASDAQ:GENE) shares closed at $1.90 on last trade day, by losing -5.00%. Stock 52 week range is $1.30 – $3.35. Company’s market capitalization is $30.11 million.
Idenix Pharmaceuticals (NASDAQ:IDIX) had its price target lowered by JMP Securities from $5.00 to $3.00 in a research note issued to investors on Thursday, American Banking and Market News reports. Idenix Pharmaceuticals Inc (NASDAQ:IDIX) stock decreased -6.52% and finished the last session at $6.88. The EPS of the stock remained -0.87. Company’s market capitalization is $1.04 billion.
Epizyme (NASDAQ:EPZM) major shareholder Celgene European Investment Co acquired 340,000 shares of Epizyme stock in a transaction that occurred on Monday, February 10th. The stock was purchased at an average price of $29.25 per share, with a total value of $9,945,000.00. Epizyme Inc (NASDAQ:EPZM) stock opened at $33.05 in last trading session and closed at $30.60. The 52 week range of the stock is $18.10 – $45.72 and the day range was $30.51 – $34.01.